Controlled Human Infection Model for Hepatitis C Virus Vaccine Development: Is It Time to Be Real?
作者信息
Liang T Jake, Feld Jordan J, Shoukry Naglaa H, Thomas David L
机构信息
Liver Diseases Branch, National Institute of Diabetics and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, Canada.
出版信息
Clin Infect Dis. 2023 Aug 14;77(Suppl 3):S215. doi: 10.1093/cid/ciad343.
Abstract
摘要
相似文献
1
Controlled Human Infection Model for Hepatitis C Virus Vaccine Development: Is It Time to Be Real?用于丙型肝炎病毒疫苗研发的人体感染控制模型：是时候认真对待了吗？
Clin Infect Dis. 2023 Aug 14;77(Suppl 3):S215. doi: 10.1093/cid/ciad343.
2
Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.E2 高变区 (HVR1) 在重组丙型肝炎病毒疫苗免疫原性中的作用。
J Virol. 2018 May 14;92(11). doi: 10.1128/JVI.02141-17. Print 2018 Jun 1.
3
Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice.细胞培养来源的丙型肝炎病毒诱导的中和抗体可预防小鼠感染。
Gastroenterology. 2013 Aug;145(2):447-55.e1-4. doi: 10.1053/j.gastro.2013.05.007. Epub 2013 May 11.
4
Can Broadly Neutralizing Monoclonal Antibodies Lead to a Hepatitis C Virus Vaccine?广谱中和单克隆抗体能否带来丙型肝炎病毒疫苗？
Trends Microbiol. 2018 Oct;26(10):854-864. doi: 10.1016/j.tim.2018.04.002. Epub 2018 Apr 24.
5
A Hepatitis C Virus DNA Vaccine Encoding a Secreted, Oligomerized Form of Envelope Proteins Is Highly Immunogenic and Elicits Neutralizing Antibodies in Vaccinated Mice.一种编码包膜蛋白分泌寡聚形式的丙型肝炎病毒 DNA 疫苗在接种小鼠中具有高度免疫原性，并诱导中和抗体。
Front Immunol. 2019 May 24;10:1145. doi: 10.3389/fimmu.2019.01145. eCollection 2019.
6
[Hepatitis C virus vaccine].[丙型肝炎病毒疫苗]
Nihon Rinsho. 2008 Oct;66(10):1961-4.
7
Antibody Responses to Immunization With HCV Envelope Glycoproteins as a Baseline for B-Cell-Based Vaccine Development.免疫 HCV 包膜糖蛋白的抗体反应作为基于 B 细胞的疫苗开发的基础。
Gastroenterology. 2020 Mar;158(4):1058-1071.e6. doi: 10.1053/j.gastro.2019.11.282. Epub 2019 Dec 4.
8
Hepatitis C Virus Neutralizing Antibodies: Is a Vaccine Still Possible?丙型肝炎病毒中和抗体：疫苗是否仍然可行？
Cell Host Microbe. 2018 Nov 14;24(5):620-621. doi: 10.1016/j.chom.2018.10.017.
9
Antibodies Targeting Novel Neutralizing Epitopes of Hepatitis C Virus Glycoprotein Preclude Genotype 2 Virus Infection.靶向丙型肝炎病毒糖蛋白新型中和表位的抗体可预防2型病毒感染。
PLoS One. 2015 Sep 25;10(9):e0138756. doi: 10.1371/journal.pone.0138756. eCollection 2015.
10
Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG.来自与Fc IgG融合的前体蛋白的重组gpE1/gpE2异源二聚体疫苗抗原的天然折叠
J Virol. 2016 Dec 16;91(1). doi: 10.1128/JVI.01552-16. Print 2017 Jan 1.
引用本文的文献
1
Receptor transporter protein 4 (RTP4)-mediated repression of hepatitis C virus replication in mouse cells.受体转运蛋白4（RTP4）介导的对小鼠细胞中丙型肝炎病毒复制的抑制作用。
PLoS Pathog. 2025 Sep 8;21(9):e1013412. doi: 10.1371/journal.ppat.1013412. eCollection 2025 Sep.
2
Immunological and senescence biomarker profiles in patients after spontaneous clearance of hepatitis C virus: gender implications for long-term health risk.丙型肝炎病毒自发清除后患者的免疫和衰老生物标志物谱：性别对长期健康风险的影响
Immun Ageing. 2023 Nov 17;20(1):62. doi: 10.1186/s12979-023-00387-z.
Zotero 插件